Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Pharmaceutical Obtains Approval For Risperdal Injection In Japan

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Janssen Pharmaceutical K.K. April 24 obtained manufacturing and marketing approval of schizophrenia drug Risperdal (risperidone) injection in Japan. Compared to current risperidone tablets that require twice-daily dosage, the new approval calls for one injection every two weeks. One of the major products for Janssen Pharma, risperidone's sales in Japan have dropped due to Japanese drug price reduction policy. The company aims to offset the decline with the launch of the new injection product. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071460

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel